A BILL 
To amend title XIX of the Social Security Act to prevent 
the misclassification of drugs for purposes of the Med-
icaid drug rebate program. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Right Rebate Act of 
4
2019’’. 
5
22:42 Feb 11, 2019
H937
2 
•HR 937 IH
SEC. 2. PREVENTING THE MISCLASSIFICATION OF DRUGS 
1
UNDER THE MEDICAID DRUG REBATE PRO-
2
GRAM. 
3
(a) APPLICATION OF CIVIL MONEY PENALTY FOR 
4
MISCLASSIFICATION
OF
COVERED
OUTPATIENT 
5
DRUGS.— 
6
(1) IN GENERAL.—Section 1927(b)(3) of the 
7
Social Security Act (42 U.S.C. 1396r–8(b)(3)) is 
8
amended— 
9
(A) in the paragraph heading, by inserting 
10
‘‘AND DRUG PRODUCT’’ after ‘‘PRICE’’; 
11
(B) in subparagraph (A)— 
12
(i) in clause (ii), by striking ‘‘; and’’ 
13
at the end and inserting a semicolon; 
14
(ii) in clause (iii), by striking the pe-
15
riod at the end and inserting a semicolon; 
16
(iii) in clause (iv), by striking the 
17
semicolon at the end and inserting ‘‘; 
18
and’’; and 
19
(iv) by inserting after clause (iv) the 
20
following new clause: 
21
‘‘(v) not later than 30 days after the 
22
last day of each month of a rebate period 
23
under the agreement, such drug product 
24
information as the Secretary shall require 
25
22:42 Feb 11, 2019
H937
3 
•HR 937 IH
for each of the manufacturer’s covered out-
1
patient drugs.’’; and 
2
(C) in subparagraph (C)— 
3
(i) in clause (ii), by inserting ‘‘, in-
4
cluding information related to drug pric-
5
ing, drug product information, and data 
6
related to drug pricing or drug product in-
7
formation,’’ after ‘‘provides false informa-
8
tion’’; and 
9
(ii) by adding at the end the following 
10
new clauses: 
11
‘‘(iii) 
MISCLASSIFIED
OR 
12
MISREPORTED INFORMATION.— 
13
‘‘(I) IN
GENERAL.—Any manu-
14
facturer with an agreement under this 
15
section that knowingly (as defined in 
16
section 1003.110 of title 42, Code of 
17
Federal Regulations (or any successor 
18
regulation)) misclassifies a covered 
19
outpatient drug, such as by knowingly 
20
submitting incorrect drug category in-
21
formation, is subject to a civil money 
22
penalty for each covered outpatient 
23
drug that is misclassified in an 
24
amount not to exceed 2 times the 
25
22:42 Feb 11, 2019
H937
4 
•HR 937 IH
amount of the difference, as deter-
1
mined by the Secretary, between— 
2
‘‘(aa) the total amount of 
3
rebates that the manufacturer 
4
paid with respect to the drug to 
5
all States for all rebate periods 
6
during 
which 
the 
drug 
was 
7
misclassified; and 
8
‘‘(bb) the total amount of 
9
rebates that the manufacturer 
10
would have been required to pay, 
11
as determined by the Secretary, 
12
with respect to the drug to all 
13
States for all rebate periods dur-
14
ing which the drug was misclassi-
15
fied if the drug had been cor-
16
rectly classified. 
17
‘‘(II) OTHER
PENALTIES
AND 
18
RECOVERY
OF
UNDERPAID
RE-
19
BATES.—The civil money penalties de-
20
scribed in subclause (I) are in addi-
21
tion to other penalties as may be pre-
22
scribed by law and any other recovery 
23
of the underlying underpayment for 
24
rebates due under this section or the 
25
22:42 Feb 11, 2019
H937
5 
•HR 937 IH
terms of the rebate agreement as de-
1
termined by the Secretary. 
2
‘‘(iv) INCREASING
OVERSIGHT
AND 
3
ENFORCEMENT.—Each year the Secretary 
4
shall retain, in addition to any amount re-
5
tained by the Secretary to recoup inves-
6
tigation and litigation costs related to the 
7
enforcement of the civil money penalties 
8
under this subparagraph and subsection 
9
(c)(4)(B)(ii)(III), an amount equal to 25 
10
percent of the total amount of civil money 
11
penalties collected under this subparagraph 
12
and subsection (c)(4)(B)(ii)(III) for the 
13
year, and such retained amount shall be 
14
available to the Secretary, without further 
15
appropriation and until expended, for ac-
16
tivities related to the oversight and en-
17
forcement of this section and agreements 
18
under this section, including— 
19
‘‘(I) improving drug data report-
20
ing systems; 
21
‘‘(II) evaluating and ensuring 
22
manufacturer compliance with rebate 
23
obligations; and 
24
22:42 Feb 11, 2019
H937
6 
•HR 937 IH
‘‘(III) oversight and enforcement 
1
related to ensuring that manufactur-
2
ers accurately and fully report drug 
3
information, including data related to 
4
drug classification.’’; and 
5
(iii) in subparagraph (D)— 
6
(I) in clause (iv), by striking ‘‘, 
7
and’’ and inserting a comma; 
8
(II) in clause (v), by striking 
9
‘‘subsection (f).’’ and inserting ‘‘sub-
10
section (f), and’’; and 
11
(III) by inserting after clause (v) 
12
the following new clause: 
13
‘‘(vi) in the case of categories of drug 
14
product or classification information that 
15
were not considered confidential by the 
16
Secretary on the day before the date of the 
17
enactment of this clause.’’. 
18
(2) TECHNICAL AMENDMENTS.— 
19
(A) Section 1903(i)(10) of the Social Secu-
20
rity Act (42 U.S.C. 1396b(i)(10)) is amended— 
21
(i) in subparagraph (C)— 
22
(I) by adjusting the left margin 
23
so as to align with the left margin of 
24
subparagraph (B); and 
25
22:42 Feb 11, 2019
H937
7 
•HR 937 IH
(II) by striking ‘‘, and’’ and in-
1
serting a semicolon; 
2
(ii) in subparagraph (D), by striking 
3
‘‘; or’’ and inserting ‘‘; and’’; and 
4
(iii) by adding at the end the fol-
5
lowing new subparagraph: 
6
‘‘(E) with respect to any amount expended 
7
for a covered outpatient drug for which a sus-
8
pension under section 1927(c)(4)(B)(ii)(II) is in 
9
effect; or’’. 
10
(B) Section 1927(b)(3)(C)(ii) of the Social 
11
Security Act (42 U.S.C. 1396r–8(b)(3)(C)(ii)) 
12
is amended by striking ‘‘subsections (a) and 
13
(b)’’ and inserting ‘‘subsections (a), (b), (f)(3), 
14
and (f)(4)’’. 
15
(b) RECOVERY OF UNPAID REBATE AMOUNTS DUE 
16
TO
MISCLASSIFICATION
OF
COVERED
OUTPATIENT 
17
DRUGS.— 
18
(1) IN GENERAL.—Section 1927(c) of the So-
19
cial Security Act (42 U.S.C. 1396r–8(c)) is amended 
20
by adding at the end the following new paragraph: 
21
‘‘(4) RECOVERY OF UNPAID REBATE AMOUNTS 
22
DUE
TO
MISCLASSIFICATION
OF
COVERED
OUT-
23
PATIENT DRUGS.— 
24
22:42 Feb 11, 2019
H937
8 
•HR 937 IH
‘‘(A) IN GENERAL.—If the Secretary deter-
1
mines that a manufacturer with an agreement 
2
under this section paid a lower per-unit rebate 
3
amount to a State for a rebate period as a re-
4
sult of the misclassification by the manufac-
5
turer of a covered outpatient drug (without re-
6
gard to whether the manufacturer knowingly 
7
made the misclassification or should have 
8
known that the misclassification would be 
9
made) than the per-unit rebate amount that the 
10
manufacturer would have paid to the State if 
11
the drug had been correctly classified, the man-
12
ufacturer shall pay to the State an amount 
13
equal to the product of— 
14
‘‘(i) the difference between— 
15
‘‘(I) the per-unit rebate amount 
16
paid to the State for the period; and 
17
‘‘(II) the per-unit rebate amount 
18
that the manufacturer would have 
19
paid to the State for the period, as 
20
determined by the Secretary, if the 
21
drug had been correctly classified; and 
22
‘‘(ii) the total units of the drug paid 
23
for under the State plan in the period. 
24
22:42 Feb 11, 2019
H937
9 
•HR 937 IH
‘‘(B) 
AUTHORITY
TO
CORRECT 
1
MISCLASSIFICATIONS.— 
2
‘‘(i) IN
GENERAL.—If the Secretary 
3
determines that a manufacturer with an 
4
agreement under this section has misclassi-
5
fied a covered outpatient drug (without re-
6
gard to whether the manufacturer know-
7
ingly made the misclassification or should 
8
have known that the misclassification 
9
would be made), the Secretary shall notify 
10
the manufacturer of the misclassification 
11
and require the manufacturer to correct 
12
the misclassification in a timely manner. 
13
‘‘(ii) ENFORCEMENT.—If, after receiv-
14
ing notice of a misclassification from the 
15
Secretary under clause (i), a manufacturer 
16
fails to correct the misclassification by 
17
such time as the Secretary shall require, 
18
until the manufacturer makes such correc-
19
tion, the Secretary may— 
20
‘‘(I) correct the misclassification 
21
on behalf of the manufacturer; 
22
‘‘(II) suspend the misclassified 
23
drug and the drug’s status as a cov-
24
ered outpatient drug under the manu-
25
22:42 Feb 11, 2019
H937
10 
•HR 937 IH
facturer’s national rebate agreement; 
1
or 
2
‘‘(III) impose a civil money pen-
3
alty (which shall be in addition to any 
4
other recovery or penalty which may 
5
be available under this section or any 
6
other provision of law) for each rebate 
7
period during which the drug is 
8
misclassified not to exceed an amount 
9
equal to the product of— 
10
‘‘(aa) the total number of 
11
units of each dosage form and 
12
strength of such misclassified 
13
drug paid for under any State 
14
plan during such a rebate period; 
15
and 
16
‘‘(bb) 23.1 percent of the av-
17
erage manufacturer price for the 
18
dosage form and strength of such 
19
misclassified drug. 
20
‘‘(C) REPORTING AND TRANSPARENCY.— 
21
‘‘(i) IN
GENERAL.—The Secretary 
22
shall submit a report to Congress on at 
23
least an annual basis that includes infor-
24
mation on the covered outpatient drugs 
25
22:42 Feb 11, 2019
H937
11 
•HR 937 IH
that have been identified as misclassified, 
1
the steps taken to reclassify such drugs, 
2
the actions the Secretary has taken to en-
3
sure the payment of any rebate amounts 
4
which were unpaid as a result of such 
5
misclassification, and a disclosure of ex-
6
penditures from the fund created in sub-
7
section (b)(3)(C)(iv), including an account-
8
ing of how such funds have been allocated 
9
and spent in accordance with such sub-
10
section. 
11
‘‘(ii) PUBLIC ACCESS.—The Secretary 
12
shall make the information contained in 
13
the report required under clause (i) avail-
14
able to the public on a timely basis. 
15
‘‘(D) OTHER PENALTIES AND ACTIONS.— 
16
Actions taken and penalties imposed under this 
17
clause shall be in addition to other remedies 
18
available to the Secretary including terminating 
19
the manufacturer’s rebate agreement for non-
20
compliance with the terms of such agreement 
21
and shall not exempt a manufacturer from, or 
22
preclude the Secretary from pursuing, any civil 
23
money penalty under this title or title XI, or 
24
22:42 Feb 11, 2019
H937
12 
•HR 937 IH
any other penalty or action as may be pre-
1
scribed by law.’’. 
2
(2) OFFSET OF RECOVERED AMOUNTS AGAINST 
3
MEDICAL
ASSISTANCE.—Section 1927(b)(1)(B) of 
4
the 
Social 
Security 
Act 
(42 
U.S.C. 
1396r– 
5
8(b)(1)(B)) is amended by inserting ‘‘, including 
6
amounts received by a State under subsection 
7
(c)(4),’’ after ‘‘in any quarter’’. 
8
(c) 
CLARIFYING
DEFINITIONS.—Section 
9
1927(k)(7)(A) of the Social Security Act (42 U.S.C. 
10
1396r–8(k)(7)(A)) is amended— 
11
(1) by striking ‘‘an original new drug applica-
12
tion’’ and inserting ‘‘a new drug application’’ each 
13
place it appears; 
14
(2) in clause (i), by inserting ‘‘but including a 
15
drug product approved for marketing as a non-pre-
16
scription drug that is regarded as a covered out-
17
patient drug under paragraph (4)’’ after ‘‘drug de-
18
scribed in paragraph (5)’’; 
19
(3) in clause (ii), by striking ‘‘was originally 
20
marketed’’ and inserting ‘‘is marketed’’; and 
21
(4) in clause (iv)— 
22
(A) by inserting ‘‘, including a drug prod-
23
uct approved for marketing as a non-prescrip-
24
tion drug that is regarded as a covered out-
25
22:42 Feb 11, 2019
H937
13 
•HR 937 IH
patient drug under paragraph (4),’’ after ‘‘cov-
1
ered outpatient drug’’; and 
2
(B) by adding at the end the following new 
3
sentence: ‘‘Such term also includes a covered 
4
outpatient drug that is a biological product li-
5
censed, produced, or distributed under a bio-
6
logics license application approved by the Food 
7
and Drug Administration.’’ 
8
(d) EXCLUSION OF MANUFACTURERS FOR KNOWING 
9
MISCLASSIFICATION
OF
COVERED
OUTPATIENT 
10
DRUGS.—Section 1128(b) of the Social Security Act (42 
11
U.S.C. 1320a–7(b)) is amended by adding at the end the 
12
following new paragraph: 
13
‘‘(17) KNOWINGLY
MISCLASSIFYING
COVERED 
14
OUTPATIENT DRUGS.—Any manufacturer or officer, 
15
director, agent, or managing employee of such man-
16
ufacturer that knowingly misclassifies a covered out-
17
patient drug under an agreement under section 
18
1927, knowingly fails to correct such misclassifica-
19
tion, or knowingly provides false information related 
20
to drug pricing, drug product information, or data 
21
related to drug pricing or drug product informa-
22
tion.’’. 
23
(e) EFFECTIVE DATE.—The amendments made by 
24
this section shall take effect on the date of the enactment 
25
22:42 Feb 11, 2019
H937
14 
•HR 937 IH
of this Act, and shall apply to covered outpatient drugs 
1
supplied by manufacturers under agreements under sec-
2
tion 1927 of the Social Security Act (42 U.S.C. 1396r– 
3
8) on or after such date. 
4
Æ 
22:42 Feb 11, 2019
H937
